Patents by Inventor Marc A. Bruce

Marc A. Bruce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
    Patent number: 8546429
    Abstract: The present invention relates to certain trisubstituted aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: October 1, 2013
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Robert M. Jones, Graeme Semple, Yifeng Xiong, Young-Jun Shin, Albert S. Ren, Imelda Calderon, Beatriz Fioravanti, Jin Sun Karoline Choi, Juerg Lehmann, Marc Bruce
  • 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
    Publication number: 20110112060
    Abstract: The present invention relates to certain trisubstituted aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
    Type: Application
    Filed: October 13, 2010
    Publication date: May 12, 2011
    Applicant: Arena Pharmaceuticals, Inc.
    Inventors: Robert M. Jones, Graeme Semple, Yifeng Xiong, Young-Jun Shin, Albert S. Ren, Imelda Calderon, Beatriz Fioravanti, Jin Sun Karoline Choi, Juerg Lehmann, Marc A. Bruce
  • Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
    Patent number: 7838525
    Abstract: The present invention relates to certain trisubstituted aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: November 23, 2010
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Robert M. Jones, Graem Semple, Yifeng Xiong, Young-Jun Shin, Albert S. Ren, Imelda Calderon, Beatriz Fioravanti, Jin Sun Karoline Choi, Juerg Lehmann, Marc A. Bruce
  • Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
    Patent number: 7470699
    Abstract: The present invention relates to certain trisubstituted aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: December 30, 2008
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Robert M. Jones, Graeme Semple, Yifeng Xiong, Young-Jun Shin, Albert S. Ren, Imelda Calderon, Beatriz Fioravanti, Jin Sun Karoline Choi, Juerg Lehmann, Marc A. Bruce
  • Gpr41 and Modulators Thereof for the Treatment of Insulin-Related Disorders
    Publication number: 20080312277
    Abstract: The present invention relates to a method for identifying a glycemic stabilizing compound by: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is modulated, where a modulation in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. In addition, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is increased, wherein an increase in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. Further, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is decreased, wherein a decrease in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound.
    Type: Application
    Filed: November 1, 2005
    Publication date: December 18, 2008
    Inventors: James N. Leonard, Zhi Liang Chu, Marc A. Bruce, P. Douglas Boatman
  • Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the phophylaxis and treatment of disorders related thereto
    Publication number: 20070155763
    Abstract: The present invention relates to certain trisubstituted aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
    Type: Application
    Filed: November 21, 2006
    Publication date: July 5, 2007
    Applicant: Arena Pharmaceuticals, Inc.
    Inventors: Robert Jones, Graeme Semple, Yifeng Xiong, Young-Jun Shin, Albert Ren, Imelda Calderon, Beatriz Fioravanti, Jin Sun Karoline Choi, Juerg Lehmann, Marc Bruce
  • Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
    Publication number: 20050070562
    Abstract: The present invention relates to certain trisubstituted aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
    Type: Application
    Filed: July 9, 2004
    Publication date: March 31, 2005
    Inventors: Robert Jones, Graeme Semple, Yifeng Xiong, Young-Jun Shin, Albert Ren, Imelda Calderon, Beatriz Fioravanti, Jin Sun Karoline Choi, Juerg Lehmann, Marc Bruce
  • Manufacture of polysulfones
    Patent number: 6548622
    Abstract: Polysulfones are manufactured by reacting a sulfuric acid or sulfur trioxide with a bireactive aromatic compound, using as a “promoter” a carboxylic acid anhydride. The product polymers are useful as molding resins.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: April 15, 2003
    Assignee: E. I. du Pont de Nemours and Company
    Inventor: Marc Bruce Goldfinger
  • Manufacture of polyketones
    Patent number: 6538098
    Abstract: Polyketones are manufactured by reacting an aromatic carboxylic acid with a biractive aromatic compound, using as a catalyst a combination of a carboxylic acid anhydride and phosphoric acid, or equivalent thereof. The product polymers are useful as molding resins.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: March 25, 2003
    Assignee: E. I. du Pont de Nemours and Company
    Inventor: Marc Bruce Goldfinger
  • Alkylamine derivatives of dihydropyridine NPY antagonists
    Patent number: 6479482
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprises of amino and piperazine derivatives of 4-phenyl-1,4-dihydropyridines of Formula 1. where X is CH or N As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: May 10, 2001
    Date of Patent: November 12, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Graham S. Poindexter, Marc Bruce, Sing-Yuen Sit, Scott W. Martin
  • NPY antagonists: spiroisoquinolinone derivatives
    Patent number: 6348472
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of spiroisoquinolinone derivatives of Formula I. As antagonists of NPY-induced feeding behavior, these compounds and known analogs are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: February 19, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Graham S. Poindexter, Ildiko Antal, Leah M. Giupponi, Robert H. Stoffel, Marc A. Bruce
  • Alkylamine derivatives of dihydropyridine NPY antagonists
    Publication number: 20020019384
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprises of amino and piperazine derivatives of 4-phenyl-1,4-dihydropyridines of Formula 1.
    Type: Application
    Filed: May 10, 2001
    Publication date: February 14, 2002
    Inventors: Graham S. Poindexter, Marc Bruce, Sing-Yuen Sit, Scott W. Martin
  • Thermoplastic elastomers
    Patent number: 6300463
    Abstract: Thermoplastic elastomeric polymers which contain polyether blocks having tetramethylene ether repeat units, and polyamide blocks, have improved elastomeric properties such as higher unload power and lower tensile set, when the polyether blocks also contain 2-alkyltetramethylene ether repeat units. The polymers are useful as molding resins and for fibers.
    Type: Grant
    Filed: January 4, 2000
    Date of Patent: October 9, 2001
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Garret Daniel Figuly, Marc Bruce Goldfinger
  • Dihydropyridine NPY antagonists: cyanoguanidine derivatives
    Patent number: 6001836
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of cyanoguanidine derivatives of 4-phenyl-1,4-dihydropyridines of Formula (I). ##STR1## As antagonists of NPY-induced feeding behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: December 14, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: Graham S. Poindexter, R. Thomas Swann, Marc A. Bruce, Mendi A. Morton, Yazhong Huang, Sing-Yuen Sit, James Guy Breitenbucher
  • Dihydropyrimidone derivatives as NPY antagonists
    Patent number: 5889016
    Abstract: The present invention provides a series of non-peptidergic antagonists of NPY comprising piperidine derivatives of 4-phenyl-1,4-dihydropyrimidinones of the Formula I ##STR1## wherein R, R.sup.1 and R.sup.2 are defined herein. As antagonists of NPY-induced feeding behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: January 20, 1998
    Date of Patent: March 30, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: Marc A. Bruce, Graham S. Poindexter, Graham Johnson
  • Ethylamino carbazole melatonergic agents
    Patent number: 5677328
    Abstract: Novel substituted carbazole compounds of Formula I are active as melatonergic agents: ##STR1## wherein: R.sub.1 is C(O)R.sub.3 or SO.sub.2 R.sub.4 ;R.sub.2 is H or C.sub.1-6 alkoxy;R.sub.3 is C.sub.1-6 alkyl, (CH.sub.2).sub.n SR.sub.4, (CH.sub.2).sub.n OR.sub.4, (CH.sub.2).sub.n SO.sub.2 R.sub.4, or NHR.sub.4 ;R.sub.4 is C.sub.1-4 alkyl; andm is 1 or 2; andn is 1 to 4.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: October 14, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Katherine S. Takaki, Marc A. Bruce, Graham S. Poindexter, Brett T. Watson, Joseph P. Yevich
  • Dihydropyridine NPY antagonists: piperidine derivatives
    Patent number: 5668151
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of piperidine and tetrahydropyridine derivatives of 4-phenyl-1,4-dihydropyridines of Formula I. ##STR1## As antagonists of NPY-induced feeding behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: May 8, 1996
    Date of Patent: September 16, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Graham S. Poindexter, Marc Bruce, Graham Johnson, Karen LeBoulluec, Charles P. Sloan
  • Dihydropyridine npy antagonists: piperazine derivatives
    Patent number: 5635503
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of piperazine and homopiperazine derivatives of 4-phenyl-1,4-dihydropyridines of Formula (I). ##STR1## As antagonists of NPY-induced feeding behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 3, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Graham S. Poindexter, Marc Bruce, Graham Johnson, Michael Kozlowski, Karen LeBoulluec, Ivo Monkovic, Ramakrishna Seethala, Charles P. Sloan
  • Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives
    Patent number: 5554621
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of nitrogen heterocyclic derivatives of 4-phenyl-1,4-dihydropyridines of Formula (I). ##STR1## As antagonists of NPY-induced feeding behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 10, 1996
    Assignee: Bristol-Myers Squibb Company
    Inventors: Graham S. Poindexter, Marc Bruce, Graham Johnson, Karen LeBoulluec, Jeffrey W. Noonan